BRIDGEBIO PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.88 USD | +2.26% |
|
+0.57% | -38.37% |
| Sales 2024 * | 137M 10.99B | Sales 2025 * | 215M 17.24B | Capitalization | 4.66B 373B |
|---|---|---|---|---|---|
| Net income 2024 * | -613M -49.07B | Net income 2025 * | -584M -46.75B | EV / Sales 2024 * | 44.2 x |
| Net Debt 2024 * | 1.42B 114B | Net Debt 2025 * | 1.25B 99.75B | EV / Sales 2025 * | 27.4 x |
| P/E ratio 2024 * |
-7.72
x | P/E ratio 2025 * |
-7.95
x | Employees | 553 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on BridgeBio Pharma, Inc.
More recommendations
More press releases
| 1 day | +2.26% | ||
| 1 week | +0.57% | ||
| Current month | -19.53% | ||
| 1 month | -16.40% | ||
| 3 months | -30.77% | ||
| 6 months | -0.76% | ||
| Current year | -38.37% |
1 week
23.68
26.26
1 month
23.6831.22
Current year
23.6841.04
1 year
12.7544.32
3 years
4.9865.33
5 years
4.9873.50
10 years
4.9873.50
| Managers | Title | Age | Since |
|---|---|---|---|
Neil Kumar
FOU | Founder | 45 | 31/12/14 |
Charles Homcy
FOU | Founder | 75 | 31/12/14 |
| Founder | 73 | 31/12/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
James Momtazee
BRD | Director/Board Member | 52 | 29/02/16 |
| Founder | 73 | 31/12/14 | |
Fred Hassan
BRD | Director/Board Member | 78 | 16/08/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.35% | 2 M€ | -.--% | ||
| 0.12% | 7 M€ | -.--% | - | |
| 0.11% | 0 M€ | 0.00% | - | |
| 0.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 24.88 | +2.26% | 1,049,219 |
| 25/04/24 | 24.33 | -2.80% | 1,759,684 |
| 24/04/24 | 25.03 | -1.69% | 1,540,280 |
| 23/04/24 | 25.46 | +1.56% | 1,223,615 |
| 22/04/24 | 25.07 | +1.33% | 2,123,116 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
Sector
Pharmaceuticals
Calendar
01/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
24.88
USD
Average target price
50.75
USD
Spread / Average Target
+103.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.37% | 4.66B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- BBIO Stock
